SpicyIP

APRIL 10, 2024

In the last few days, the Madras and Delhi High Courts have passed a few significant orders on these topics. Let’s take a look at these three orders in this quick tidbit. More than a year later, the Ceritinib controversy has popped up again, this time Natco seeking vacation of the interim injunction.

Patent 45

Patent Cease and Desist Invention Art 45

Velocity of Content

APRIL 18, 2023

Novartis, for instance, has spent the last several years developing a state-of-the-art advanced analytics platform centered on data science, called Nerve Live. For example, analytics embedded within a company’s information management system could provide capabilities such as topic trending or correlating topics related to a search term.

Art 98

Art Publishing Technology Copyright 98

The IPKat

NOVEMBER 21, 2021

As part of the 21 for 2021 project , CREATe posted about the empirical evidence on copyright exceptions, from the oldest study on the topic to future research directions. The annual review covers topics such as the definition of a work, authorship and moral rights. The review is published in 4 different parts!

Blogging 73

Blogging IP Moral Rights Copyright 73

SpicyIP

SEPTEMBER 11, 2023

He wrote detailed posts on this topic later here and here. Talking about this topic, the issue of Judicial Recusals also shouldn’t be left untouched – an issue that has been the heart of several IP controversies, notably the Novartis dispute.

IP 105

IP Reporting Plagiarism Government 105

The IPKat

MARCH 28, 2022

The conference lasted almost three days and with a large number of topics having been discussed. The IPKat reports on some of the trends and topics from the conference below. The original conference program (which was only slightly amended due to some covid-related absences).

Reporting 76

Reporting Litigation Patent Confidentiality 76

The IPKat

SEPTEMBER 4, 2023

The judge also found Yeda to be entirely consistent with the (latest) CJEU case law on the topic, specifically Santen ( C-673/18 ) (para. Yeda concluded that, under the SPC Regulation , " how a medicinal product is used does not form part of the identification of the product itself ”.

Art 117

Art Marketing Marketing Patent 117

Patently-O

SEPTEMBER 26, 2022

Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Sanofi as well as with the likely upcoming petition in Novartis Pharm. Accord Healthcare, Inc., 4th 1013 (Fed. 2022) (written description).

Patent Law 125

Patent Law Law Patent Invention 125